Aarti Pharmalabs Ltd Q3 FY2024 Concall Summary

Key Takeaways

• CDMO/CMO breakout quarter: The segment surged to 14.2% of revenue (from 7.2%), driven by significant customer orders, and management sees a path to 20-25% of revenue in 2-3 years.
• Margin expansion despite topline flatness: Gross margin hit 46% (vs. 41-42% normally) as lower raw material costs, a richer export mix, and the CDMO ramp more than offset Xanthine pricing pressure.
• Xanthine pricing pain persists, but volume and cost tailwinds cushion the blow: YTD volumes grew ~20%, and management expects China-led dumping to end in a couple of quarters, though pricing pressure is anticipated to continue till mid-next year.
• A big capex bet is now underway: The Atali greenfield site (Phase 1: Rs. 375 crore) and a Rs. 400-500 crore total capex plan over 12-18 months signal a long-dated capacity build for regulated CDMO customers.
• What to watch next quarter: Whether the Xanthine raw material project (starting Q4) begins to ease import dependency, the pace of CDMO order conversion from the 20-product R&D pipeline, and any signal that China pharma pricing is mirroring the chemical sector recovery.

CDMO/CMO: The Inflection Quarter

• Revenue share doubled sequentially: CDMO/CMO jumped from 7.2% to 14.2% of total revenue in Q3, propelled by significant customer orders that materialized during the quarter.
• Pipeline depth supports the ambition: The portfolio now spans 19 commercial products and 20 R&D-stage products across 16+ clients, with one new customer, three new commercial products, and six new R&D products added in Q3 alone.
• 40-50% growth anticipated this year: Management expects the segment to sustain that pace over the full year, with the revenue share reaching at least 20% and potentially 25% or higher in the next 2-3 years, contingent on customer-side commercialization.
• Capacity is being diverted to feed the opportunity: Some API/intermediate capacity has already been shifted to CDMO/CMO utilization, which explains the slight sequential decline in API/intermediate revenue.

Rashesh Gogri: "Next two to three years, yes, it has a chance to become 20 to 25% of the total revenue or even bigger because it depends on how the products are commercializing at the customer end, and depending on that, we will have more visibility, but I think going forward we see this number to at least reach this 20% mark and go above it."

Xanthine: Pricing Pressure, Volume Offsets, and a China Recovery Bet

• Pricing pressure is real but margin impact is muted: Lower Xanthine derivative prices compress the revenue line, but raw material costs have fallen in parallel, so absolute margin compression has not occurred even as percentage margins shift.
• Volumes are growing strongly: YTD volume growth is close to 20% versus last year, and a further 7-8% debottlenecking is planned starting next fiscal, with one more round of debottlenecking investment being worked on.
• The China dumping thesis: Management argues that China-based dumping of these products will end in the next couple of quarters because sustainability at current low pricing has already broken in certain chemical segments, and pharma API prices should mirror that recovery as chemical input prices rise in China.
• Pricing pressure timeline is longer than the dumping timeline: Even if dumping ends soon, Xanthine pricing pressure is anticipated to continue till the middle of next year, so the recovery is a two-step process: first dumping stops, then prices normalize.
• Scale as a moat: The current pricing environment makes it difficult for any new player to enter and reach the scale at which Aarti operates, reinforcing the incumbent position.

Rashesh Gogri: "We feel that I think these all the China based dumping of these kind of products also that we have seen in other APIs will eventually end in next couple of quarters. This can't continue because everything is becoming quite challenging to others, yes."

Margins: The 46% Quarter and What It Means

• Gross margin jumped to 46% from the usual 41-42%, driven by three overlapping forces: lower sales prices were more than offset by lower raw material costs as a percentage, plus improved margin contribution from exports and the CDMO/CMO segment.
• The mix shift is structural, not just cyclical: A higher percentage of exports and the expansion of CDMO/CMO business are the stated drivers of overall margin expansion, and both trends are expected to continue.
• Management declined to bifurcate the margin impact across product mix, lower RM prices, and exports when asked, saying the company focuses on absolute number growth rather than percentage attribution.
• Segment-level margin bifurcation was also refused: Assets are common across API/intermediates and CDMO/CMO, making a clean breakup "trickier," though management indicated it may provide bifurcated margins from next year onwards.
• EBITDA growth guidance was trimmed: The earlier target of 10-12% EBITDA growth over FY23 has been lowered to 8-10%, reflecting Xanthine market changes and the postponement of certain project orders that pushed sales into the next financial year.

Capex & Capacity: The Atali Bet and Beyond

• Atali is the flagship: Phase 1 has begun with a Rs. 375 crore outlay, of which Rs. 125 crore is infrastructure alone and the balance goes to production blocks and utilities. The site can accommodate 12-15 blocks, with one block addable per year depending on customer growth.
• Why a large single site: Regulated customers and innovators resist site-to-site product transfers, so consolidating future expansion at one large manufacturing site is a strategic bet to win and retain that business.
• Total capex of Rs. 400-500 crore over the next 12-18 months, funded through a mix of internal accruals and borrowings, with projects expected to start operating within the next 15 months. The debt-to-equity target is 0.3 to 0.35.
• Other capacity additions in flight: A semi-commercial US FDA intermediate production block at Vapi is targeting completion in Q2 FY25, and a Xanthine raw material project begins in Q4 FY24 to limit import dependency.
• New API block at Tarapur has onboarded most customers, with larger products moved there to free up multipurpose block capacity; ramp-up will play out over the next 2-3 years.
• Solar capex of Rs. 90 crore has been commissioned and is expected to start operating in H2 FY25.
• Asset turnover ambition: Management is targeting more than 1x to 1.2x of net fixed assets, but acknowledges this requires a richer product mix and more value-added products.

Rashesh Gogri: "It is a large manufacturing site that we are trying to put because we would like to see, consolidate our place where we do further expansion because the regulated customers and innovators don't like us to ship the sites from one site to other site and so from that perspective, we have taken a bet on putting up this very large manufacturing site."

API & Intermediates: Steady Demand, Gradual Capacity Shift

• Demand is stable to good across steroids, anti-cancer, and lifestyle drugs, with the company operating largely in regulated and export markets. Some pricing compression exists due to overall competition, but the impact is contained.
• Revenue dipped slightly as capacity shifted to CDMO: The decline in API/intermediate revenue in Q3 is attributed to capacity diversion toward CDMO/CMO utilization, not to demand weakness.
• Absolute growth expectation is modest: Management expects this business to grow, with absolute numbers around 10%, though it declined to guide on topline specifically, preferring to anchor on absolute EBITDA increase.
• New R&D center capabilities include peptides, flow chemistry, and newer reactions, with future production capabilities expected at the Atali site, signaling a technology upgrade path for the API business.

Guidance & Commitments

Key Metrics